N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

MEdical Treatment in Idiopathic Ventricular Fibrillation Patients

Sponsor: Bo Gregers Winkel • ClinicalTrials.gov ID: NCT07405229

Registry updated: 2026-09-01
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at least some patients with no apparent diagnosis are on betablocker treatment. It is not known if low-doselow dose betablocker treatment is beneficial in these patients. This study investigates the effect of betablocker treatment to reduce arrhythmic burden in IVF patients. No predictors for appropriate ICD therapy have been identified in patients with IVF. It is also explored if toxicological and/or genetic profiles, together with in depth machine learning simulation data on repolarization patterns from IVF-ECGs compared to controls, can be used as risk stratification tools. Lastly, QOL in IVF patients and the impact of beta blocker treatment will be investigated.

Interventions

  • Beta-blocker treatment group (Drug)
    The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.

Eligibility criteria

Inclusion Criteria: Resuscitated OHCA patients admitted to one of the participating hospitals. 1. Age ≥18 years 2. Suspected cardiac cause of cardiac arrest Exclusion Criteria: OHCA patients 1. With Ischemic heart disease. 2. Obvious non-cardiac cause of cardiac arrest 3. Congenital heart disease 4. Do not speak or understand Danish 5. Foreigners -

Conditions

Idiopathic Ventricular Fibrillation Cardiac Arrest, Out-Of-Hospital

Locations

  • The Heart Center, Rigshospitalet — Copenhagen, Dr., Denmark
  • Odense University Hospital — Odense, Denmark
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record